Pharma News
This Week
Sep 9, 2025
On the 9th, GI Innovation revealed that it has secured a patent for its immuno-cancer formulation.
GI Innovation announced the registration of a patent for its immuno-cancer drug GI-101A in Europe, enhancing drug stability and delivery efficiency for both intravenous and subcutaneous injections. Currently entering phase 2 trials, GI-101A has shown strong anticancer activity in combination with Keytruda. The company aims to attract European investors following this patent and recent successes with GI-102.
Sep 9, 2025
DCGI reports that 97% of CDSCO's operations have transitioned to digital formats, according to DrugsControl Media Services.
The Drugs Controller General of India, Dr. Rajeev Singh Raghuvanshi, announced that 97% of operations at the Central Drugs Standard Control Organisation (CDSCO) are now digital, resulting in a 25% reduction in inefficiencies. This digital transformation aims to enhance regulatory processes in the pharmaceutical sector.
Sep 8, 2025
AAM: Escalating issues with ongoing patent lawsuits - Drug Store News
The Association for Accessible Medicines (AAM) and the Biosimilars Council released a white paper addressing serial patent litigation by brand drug manufacturers that delays access to affordable generic and biosimilar medications. AAM's CEO, John Murphy III, urged Congress to streamline patent litigation to enhance patient access and savings. The paper includes 10 case studies highlighting affected medications.
Sep 8, 2025
Increased demand for diabetes medication used for weight loss results in shortages, according to Lancet.
High demand for semaglutide, a diabetes medication now popular for weight loss, has led to shortages for patients needing it for blood sugar management, according to a Lancet article. Eli Lilly's Mounjaro and Novo Nordisk's Wegovy are now available in India, but their high costs, exceeding ₹15,000 monthly, pose accessibility challenges, especially in low-income regions.
Sep 8, 2025
Regeneron and Bayer's attempt to prevent Sandoz from introducing an Eylea biosimilar has been unsuccessful | Lawyerly
Regeneron and Bayer have failed in their attempt to prevent Sandoz from launching a biosimilar of their popular eye medication, Eylea. This decision marks a significant development in the ongoing competition within the pharmaceutical industry.
Sep 8, 2025
Is Johnson & Johnson a Dividend Powerhouse or a Gradual Pharma Performer? - AInvest
Johnson & Johnson (JNJ) maintains a 63-year streak of annual dividend increases, supported by a 53.34% payout ratio and $19.84 billion in free cash flow. However, the company faces challenges from the 2025 patent expiration of its drug Stelara, projected to cause a $2 billion revenue shortfall. JNJ's diversification and innovation strategies are crucial for sustaining its dividend amid these pressures.
Sep 8, 2025
Korea accelerates biopharmaceutical initiatives aiming for a top-five global position by 2030.
The South Korean government is intensifying efforts to elevate its biopharma industry into the world's top five, as announced at the "Bio Innovation Forum." The "K-Bio Pharmaceutical Industry Leap Forward Strategy" aims to double exports, create three blockbuster drugs, and become the third-largest in clinical trials by 2030, leveraging AI and regulatory reforms to enhance innovation and competitiveness.
Sep 8, 2025
J&J and AbbVie: Which Healthcare Leader Comes Out on Top? - AInvest
Johnson & Johnson (JNJ) and AbbVie (ABBV) are both major players in healthcare, facing challenges from the patent cliff. JNJ's diversified portfolio and growth in its Innovative Medicine segment make it a more attractive investment compared to ABBV, which relies heavily on Humira and Skyrizi. JNJ's resilience and revenue from medical devices further enhance its investment appeal.
Sep 8, 2025
Will the FDA's approved list put an end to unlawful GLP-1 compounding? - TechTarget
The FDA has introduced a "green list" import alert to prevent unverified GLP-1 active ingredients from entering the U.S., amid concerns over illegal compounded versions of GLP-1 drugs for weight loss. The agency aims to secure the drug supply chain, but experts question the effectiveness of this strategy in addressing regulatory neglect and enforcement gaps in compounding practices.
Sep 8, 2025
Research Discovers Protein Fragment Associated with Alzheimer's That Interferes with HIV-1 Assembly in Neural Cells
A study by Northwestern Medicine published in the *Proceedings of the National Academy of Sciences* has identified a protein fragment linked to Alzheimer’s disease that disrupts HIV-1 assembly in brain cells. This finding suggests a molecular connection between Alzheimer’s and HIV-1, offering new insights into the interactions between these two conditions.
Sep 8, 2025
Dermatologist advises to cease the use of fairness creams right away, as they may lead to increased facial hair growth.
Dr. Aanchal Panth, a dermatologist, has warned against the use of fairness creams, stating they can lead to increased facial hair and redness of the skin. She emphasized the dangers of these products in a recent Instagram post, highlighting that they can thin the skin and make veins more visible.
Sep 8, 2025
Regeneron's Strategic Role in the Biotech Sector Following Presentation - AInvest
Regeneron Pharmaceuticals showcased its robust R&D pipeline at the Morgan Stanley Global Healthcare Conference, aiming to deliver over 10 blockbuster drugs across oncology and immunology. Key products include DUPIXENT, generating $4.34 billion in Q2 2025, and Libtayo. Despite challenges with EYLEA's sales decline, Regeneron remains financially strong, investing $7 billion in R&D and manufacturing to sustain growth.
Sep 8, 2025
WHO supports weight-loss medications and calls for affordable generic options - Pharmacy Business
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for treating diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are significant. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 8, 2025
Exploring Bayer's Elinzanetant and the Transformation of Menopause Treatments: An In-Depth Analysis of Non...
Bayer's elinzanetant, a first-in-class dual NK-1 and NK-3 receptor antagonist, is poised to transform the menopause therapeutics market, addressing vasomotor symptoms like hot flashes. With promising Phase III trial results and approvals in the UK and Canada, it could capture significant market share, especially with a projected $741 million annual revenue opportunity in the U.S. by 2034.
Sep 7, 2025
Summit Therapeutics encounters potential setback with lung cancer medication anticipated to be a major success.
Summit Therapeutics faces challenges with its lung cancer drug ivonescimab, as a study revealed that patients in North America and Europe experienced faster tumor progression compared to those in China. While the risk of progression decreased by 45% for Chinese patients, it only reduced by 33% for Western participants, failing to achieve statistical significance, complicating approval efforts in the U.S. and Europe.
Sep 7, 2025
Implications for Investment in GLP-1 Medications Following WHO's Inclusion in Essential Medicines List
The WHO has added GLP-1 receptor agonists, including semaglutide (Novo Nordisk’s Ozempic) and tirzepatide (Eli Lilly’s Mounjaro), to its Essential Medicines List, aiming to improve access for diabetes and obesity treatment. This move could reshape market dynamics and pricing strategies for both companies, while also encouraging generic production as patents expire.
Sep 7, 2025
Biotech Shares Increase Following ACIP's Recommendations for RSV Vaccine and Gilead's Latest Updates...
Biotech stocks surged yesterday, with the XBI index showing significant gains, driven by the Advisory Committee on Immunization Practices (ACIP) issuing recommendations for RSV vaccines. Gilead Sciences also updated its pipeline projects, enhancing investor confidence in the sector. These developments are expected to positively impact vaccine adoption rates and market dynamics for companies involved in RSV research.
Sep 7, 2025
Could Pfizer Create Millionaires? - AOL.com
Pfizer's stock has plummeted nearly 60% from its 2022 peak, primarily due to overinflated expectations following its COVID-19 vaccine success. Despite facing patent cliffs and a temporary revenue boost, analysts suggest it remains a solid long-term investment. Pfizer offers a 6.8% dividend yield, but investors may want to consider alternatives like Merck and Bristol Myers Squibb for more reliable dividends.
Sep 7, 2025
WHO includes GLP-1 medications such as Ozempic in its essential medicines list - Roya News
The WHO has updated its essential medicines list, adding key drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro for diabetes, Vertex Pharmaceuticals’ Trikafta for cystic fibrosis, and Merck’s Keytruda for various cancers. This move aims to enhance global access to these high-cost treatments, addressing critical health challenges like diabetes and obesity affecting over 1.8 billion people worldwide.
Sep 7, 2025
CVS Caremark is being sued in a class-action lawsuit regarding its coverage of Zepbound and Wegovy.
CVS Caremark is facing a class-action lawsuit for stopping coverage of Zepbound, Eli Lilly’s weight-loss drug, affecting around 200,000 patients. The lawsuit claims this decision violates federal law, as Zepbound is deemed more effective than Wegovy, a similar drug made by Novo Nordisk, which CVS now covers. CVS maintains the lawsuit is "without merit.
Sep 7, 2025
SprintRay Purchases EnvisionTEC's Dental Product Line Along with Associated Patents and Trademarks
SprintRay has acquired EnvisionTEC’s dental product portfolio, including patents, trademarks, and inventory, to enhance its 3D printing capabilities in dentistry. This acquisition grants SprintRay access to proprietary technologies and materials from EnvisionTEC, formerly known as Desktop Health. Financial terms of the deal were not disclosed.
